Institut Jules Bordet
Institut Jules Bordet
Brussels, Belgium23 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First-in-Human Study of ICT01 in Patients With Advanced Cancer | Hemic and Lymphatic Diseases, Neoplasms by Site, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-04 | NCT04243499 | |
| Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-11 | NCT02889523 | |
| A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal cancer, esophageal disorder, gastric cancer, gastric neoplasm, head and neck squamous cell carcinoma, intestinal disorder, neoplasm, non-small cell lung carcinoma, rectal disorder, squamous cell carcinoma, stomach disorder | Recruiting | Phase 1 / Phase 2 | 2026-07-29 | NCT03526835 | |
| My Personalized Breast Screening | Breast Screening | Active, not recruiting | Not applicable | 2026-07-22 | NCT03672331 | |
| Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Recruiting | Phase 2 | 2026-07-10 | NCT06558604 | |
| A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-05-22 | NCT04628494 | |
| Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment | Ovarian Epithelial Cancer Recurrent | Active, not recruiting | Phase 3 | 2026-05-20 | NCT01376752 | |
| Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Thymus Neoplasms, lymphatic system disorder, mixed neoplasm, neoplasm, thymoma, thymoma type B3 | Active, not recruiting | Phase 2 | 2026-05-15 | NCT03134118 | |
| Male Breast Cancer: Understanding the Biology for Improved Patient Care | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not stated | 2026-05-12 | NCT01101425 | |
| Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer | Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2026-03-05 | NCT06667960 | |
| Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not applicable | 2026-02-09 | NCT02308085 | |
| A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, neoplasm | Active, not recruiting | Phase 3 | 2026-02-05 | NCT03673501 | |
| A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors | Solid Tumor | Active, not recruiting | Phase 1 | 2026-01-16 | NCT06932952 | |
| Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry | Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) | Recruiting | Not stated | 2026-01-14 | NCT04220970 | |
| First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer | Unresectable Locally Advanced Colorectal Cancer; Unresectable Metastatic Colorectal Cancer | Recruiting | Phase 1 / Phase 2 | 2025-12-22 | NCT06934538 | |
| Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, prostate cancer, prostate disorder, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 1 / Phase 2 | 2025-10-07 | NCT04954599 | |
| Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors | Solid Tumor | Recruiting | Phase 1 | 2025-09-16 | NCT04064359 | |
| OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT) | Digestive System Diseases, Digestive System Neoplasms, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast cancer, breast disorder, breast neoplasm, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, male reproductive organ cancer, male reproductive system disorder, neoplasm, non-small cell lung carcinoma, prostate cancer, prostate disorder, rectal disorder, skin disorder | Recruiting | Not applicable | 2025-08-01 | NCT06462963 | |
| PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2025-07-18 | NCT06059469 | |
| Ga68-FAPI-46 PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis | Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Peritoneal Diseases, Urogenital Diseases, Urogenital Neoplasms, cancer, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, intestinal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, peritoneal neoplasm, rectal disorder | Recruiting | Not applicable | 2025-03-31 | NCT06061874 | |
| Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial) | Transplant Complication | Recruiting | Phase 2 | 2024-12-27 | NCT05762211 | |
| PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases | Genital Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic malignant neoplasm, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2024-12-09 | NCT03569241 | |
| Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations. | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Not applicable | 2024-03-06 | NCT04144387 |